Cancer Institute of NJ Adds to its Staff

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 4 No 8
Volume 4
Issue 8

NEW BRUNSWICK, NJ--Last month, The Cancer Institute of New Jersey welcomed Joseph Aisner, MD, as its new associate director of clinical science, and added four new physician/scientists to its staff.

NEW BRUNSWICK, NJ--Last month, The Cancer Institute of New Jerseywelcomed Joseph Aisner, MD, as its new associate director of clinicalscience, and added four new physician/scientists to its staff.

Dr. Aisner will also serve as chief of the Division of MedicalOncology and professor of medicine and environment and communitymedicine. He was recruited from the University of Maryland wherehe was chief of medical oncology and director of the Cancer Center.

Joseph Germino, MD, and Eric H. Rubin, MD, have joined the Instituteas assistant professors of medicine. Dr. Germino comes from YaleUniversity School of Medicine and Dr. Rubin from Dana-Farber andHarvard Medical School.

James Stephen Goydos, MD, of the University of Pittsburgh, isa new instructor of surgery, and Thomas Joseph Kearney, MD, ofthe University of Chicago, is assistant professor of surgery.

Established in 1990, The Cancer Institute of New Jersey is a partnershipof four New Jersey hospitals and medical centers, the Universityof Medicine and Dentistry of New Jersey (UMDNJ), and the UMDNJ-RobertWood Johnson Medical School.

Recent Videos
Certain bridging therapies and abundant steroid use may complicate the T-cell collection process during CAR T therapy.
Pancreatic cancer is projected to become the second-leading cause of cancer-related deaths by 2030 in the United States.
2 experts are featured in this video
2 experts are featured in this video
2 experts are featured in this video
4 KOLs are featured in this series.
Educating community practices on CAR T referral and sequencing treatment strategies may help increase CAR T utilization.
The FirstLook liquid biopsy, when used as an adjunct to low-dose CT, may help to address the unmet need of low lung cancer screening utilization.
Related Content